MetaCap

Ascentage Pharma Group International American Depository Shares (AAPG) vs Jade Biosciences (JBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Jade Biosciences (JBIO) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 27.6% versus a loss of 60.9%. Ascentage Pharma Group International American Depository Shares is the larger company by market cap ($1.12 billion vs $1.06 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AAPG-60.93%JBIO+27.58%
+133%+31%-70%
Nov 21, 20251 yearNov 20, 2026
AAPG-31.13%JBIO-83.11%
+189%+42%-106%
Jan 20, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AAPG versus JBIO key metrics
MetricAAPGJBIO
Share price$11.97$15.31
Market cap$1.12B$1.06B
1-day change-3.78%+1.66%
YTD return-54.38%-0.78%
1-year return-60.93%+27.58%
5-year return—-96.69%
EPS (TTM)$-2.26$-1.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$134.35M—
Net income (latest FY)$-55.54M$-127.41M
Gross margin97.03%—
Net margin-41.34%—
52-week high$33.09$28.00
52-week low$11.97$11.32
Distance from 52-week high-63.83%-45.32%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+271.76%+222.53%
Average volume6.97K917.21K
Shares outstanding93.33M69.19M
Employees82855
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • JBIO has outperformed AAPG by 88.5 percentage points over the past year.

About Ascentage Pharma Group International American Depository Shares

AAPG stock →

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.

Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees

About Jade Biosciences

JBIO stock →

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

AAPG vs JBIO FAQ

Which is bigger, Ascentage Pharma Group International American Depository Shares or Jade Biosciences?

Ascentage Pharma Group International American Depository Shares (AAPG) is larger, with a market capitalization of $1.12B compared with $1.06B for Jade Biosciences (JBIO).

Which stock has performed better over the past year, AAPG or JBIO?

JBIO returned +27.58% over the past 12 months, compared with -60.93% for AAPG (price return, excluding dividends). Past performance does not predict future results.

Are Ascentage Pharma Group International American Depository Shares and Jade Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons